Replies to post #2651 on RedHill Biopharma Ltd (RDHL)

[DorseyE]

RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study

+1
Zacks Equity Research
Mon, January 4, 2021, 9:41 AM EST
RedHill Biopharma Ltd. RDHL announced encouraging preliminary top-line data from the exploratory phase II study in the United States, evaluating its oral drug candidate, opaganib (Yeliva), as a potential treatment for patients hospitalized with COVID-19 pneumonia. Data from the study showed that the opaganib is safe and demonstrated greater improvement in reducing oxygen requirement by end of treatment at day 14.

Moreover, primary and secondary efficacy outcomes correlated with clinical improvement as defined by the World Health Organization (WHO) ordinal scale. Full analysis of the data is expected to be reported in the coming weeks.

Please note that a global phase II/III study is evaluating opaganib in a similar patient population. Top-line data from the study is expected during the first quarter of 2021. Opaganib is both anti-inflammatory and antiviral, which is believed to treat the cause and the effects of COVID-19.

Shares of RedHill have surged 31.6% in the past year compared with the industry’s increase of 2.7%.
https://finance.yahoo.com/news/redhill-rdhl-covid-19-drug-144102738.html

[DorseyE]

Love this part of the article........

Meanwhile, RedHill is set to start a phase II/III study on its second coronavirus candidate RHB-107 for addressing patients with symptomatic COVID-19 who do not require hospitalization. The FDA cleared an investigational new drug application for the study in November.